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ABSTRACT 
To date, a number of significant herbal drug interactions have their origins in the alteration of 
cytochrome P450 (CYP) activity by various phytochemicals. Among the most noteworthy are 
those involving St. John's wort and drugs metabolized by human CYP3A4 enzyme. This re-
view article is the continued work from our previous article (Part 1) published in this journal 
(Wanwimolruk and Prachayasittikul, 2014). This article extends the scope of the review to six 
more herbs and updates information on herbal drug interactions. These include black cohosh, 
ginseng, grape seed extract, green tea, kava, saw palmetto and some important Chinese medi-
cines are also presented. Even though there have been many studies to determine the effects 
of herbs and herbal medicines on the activity of CYP, most of them were in vitro and in ani-
mal studies. Therefore, the studies are limited in predicting the clinical relevance of herbal 
drug interactions. It appeared that the majority of the herbal medicines have no clear effects 
on most of the CYPs examined. For example, the existing clinical trial data imply that black 
cohosh, ginseng and saw palmetto are unlikely to affect the pharmacokinetics of conventional 
drugs metabolized by human CYPs. For grape seed extract and green tea, adverse herbal drug 
interactions are unlikely when they are concomitantly taken with prescription drugs that are 
CYP substrates. Although there were few clinical studies on potential CYP-mediated interac-
tions produced by kava, present data suggest that kava supplements have the ability to inhibit 
CYP1A2 and CYP2E1 significantly. Therefore, caution should be taken when patients take 
kava with CYP1A2 or CYP2E1 substrate drugs as it may enhance their therapeutic and ad-
verse effects. Despite the long use of traditional Chinese herbal medicines, little is known 
about the potential drug interactions with these herbs. Many popularly used Chinese medi-
cines have been shown in vitro to significantly change the activity of human CYP. However, 
with little confirming evidence from clinical studies, precaution should be exercised when pa-
tients are taking Chinese herbal medicines concomitantly with drugs that are CYP substrates. 
Currently there is sufficient evidence to indicate that herbal drug interactions can occur and 
may lead to serious clinical consequence. Further clinical trial research should be conducted 
to verify these herbal drug interactions. Education on herbal drug interactions and communi-
cation with patients on their use of herbal products is also important. 
 
Keywords: Herbal drug interactions, CYP, dietary supplements, herbal medicines, Chinese 
herbal medicines, drug interactions  
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INTRODUCTION 
Herbal medicines are increasingly being 
used as alternative medicines worldwide. As 
a result, it is very likely that some patients 
will take herbal medicines concomitantly 
with prescription or conventional medica-
tions. This may lead to unwanted adverse 
effects produced by herbal drug interactions. 
Many mechanisms underlying various herbal 
drug interactions have been suggested. How-
ever, the common mechanism for these in-
teractions usually involved with a modula-
tion of the absorption, metabolism, or elimi-
nation of co-administered drugs by the herb. 
Many herbs contain numerous phytochemi-
cal constituents which can induce or inhibit 
drug metabolizing enzymes such as cyto-
chrome P450 (CYP) enzymes. As most clin-
ically used drugs are metabolized by CYP 
enzymes, the changes in CYP activity initi-
ated by herbal medications will alter the 
pharmacokinetics of the co-administered 
drugs. This subsequently will reduce the 
pharmacological effects of the co-
administered drugs or cause toxicity (Gurley 
et al., 2002; Shi and Klotz, 2012). The sys-
tematic knowledge of herbal drug interac-
tion, in particular on the level of drug ab-
sorption, metabolism, elimination and drug 
transport, may help to prevent adverse drug 
effects. For these reasons, evaluations of 
herbal drug interactions associated with drug 
metabolizing enzymes, especially CYP, are 
necessary to ensure the safety of the concom-
itant use of herbal medicines. 
To continue from our previous review ar-
ticle (Part 1) published in this journal 
(Wanwimolruk and Prachayasittikul, 2014), 
the purpose of the current review is to pre-
sent the available data on herbal drug inter-
actions for the top six herbs (by sales) in the 
U.S. markets. These herbs included black 
cohosh, ginseng, grape seed extract, green 
tea, kava, and saw palmetto. Selected popu-
larly used Chinese herbal medicines are also 
presented. They are Oriental herbs widely 
used in China, Korean and other Asian coun-
tries. These include Danshen (Salvia miltior-
rhiza), Dong Quai (Angelica sinensis), Bai 
Hua She She Cao (Oldenlandia diffusa), 
Dang shen (Codonopsis tangshen) and 
Sheng Di Huang (Rehmannia glutinosa). 
These particular Chinese herbal medicines 
are known to have potential herbal drug in-
teractions. In the following sections, this re-
view article will provide some examples of 
herbal drug interactions occurred via mecha-
nism based on modulation of human CYP. 
 
Black cohosh 
Black cohosh, known botanically as 
Cimicifuga racemosa L. (Family Ranuncula-
ceae) is a shrub-like plant native to the east-
ern forests of North America. It has been 
used by Native Americans for menopausal 
symptoms such as hot flashes, premenstrual 
discomfort and dysmenorrhea (McKenna et 
al. 2001). Several preparations of black co-
hosh are available from drug stores, herbal-
ists and traditional healers are highly re-
commended as a safe and effective natural 
remedy for menopausal symptoms. Black 
cohosh is ranked among the 10 top-selling 
dietary supplements in the United States 
(Gurley et al., 2012). Potential association 
between black cohosh and hepatotoxicity has 
been questioned in Australia, Canada and 
Europe. However, a recent meta-analysis of 
five randomized controlled clinical trials and 
a critical review suggested that black cohosh 
had no adverse effects on liver function (Shi 
and Klotz, 2012). Since the risks of hormone 
replacement therapy have become known, 
black cohosh preparations are now widely 
used among women seeking alternative 
treatments for menopausal illnesses (Mahady 
et al., 2003). Massive preclinical and clinical 
studies have presented contradictory evi-
dence as regards effectiveness of black co-
hosh (Borrelli and Ernst, 2008). Early studies 
indicated that black cohosh extracts were 
effective in reducing the frequency and in-
tensity of hot flashes among premenopausal 
and postmenopausal women (Borrelli and 
Ernst, 2008 and references herein; Frei-
Kleiner et al., 2005; Wuttke et al., 2003). 
Whereas many trials showed no vasomotor 
symptom benefits (Borrelli and Ernst, 2008 
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and references herein; Geller et al., 2009; 
Liske et al., 2002). In view of the risks of 
hormone replacement therapy, many women 
will most likely continue to use black cohosh 
supplements. Therefore, the potential inter-
actions between black cohosh supplements 
and prescription drugs remain clinically rel-
evant.  
Although black cohosh has been sold as a 
dietary supplement and an over-the-counter 
medication all over the world, its chemical 
components are not completely identified. 
While spiroketal triterpene glycosides are 
not phytoestrogens but they are thought to be 
responsible for the pharmacological activity 
of black cohosh (Li and Yu, 2006; Viereck et 
al., 2005). Most of commercial black cohosh 
products are currently standardized to triter-
pene glycosides, with 23-epi-26-deoxyactein 
(also recognized as 27-deoxyactein) which is 
the most abundant constituent (van Breeman 
et al., 2010). Another group of compounds 
isolated from black cohosh were polyphenol-
ic derivatives. Thirteen compounds have 
been isolated from the rhizomes and roots of 
black cohosh (Nuntanakorn et al., 2006), in-
cluding hydroxycinnamic acid derivatives 
(e.g., caffeic acid, ferulic acid, and isoferulic 
acid), fukiic acid ester derivatives (e.g., fu-
kinolic acid and cimicifugic acids A and B), 
and piscidic acid ester derivatives (e.g., 
cimicifugic acids E and F). 
Preclinical studies including in vitro and 
animals have investigated the effects of 
black cohosh or its extract constituents on 
human CYP activity. A study in mice has 
demonstrated that liver CYP3A11 enzyme 
was induced by 7-fold in mice treated with 
500 mg/kg black cohosh for 28 days com-
pared with the control group (Pang et al., 
2011). In contrast, this induction effect was 
not found in the small intestine and kidney, 
suggesting that upregulation of mouse 
CYP3A11 by black cohosh was liver specific 
(Pang et al., 2011). It is interesting that 
mouse pregnane xenobiotic receptor (PXR) 
played an important role in the induction of 
CYP3A11; but human PXR was not activat-
ed by black cohosh. In addition, an in vitro 
study has shown that black cohosh extracts 
(75 % and 80 % ethanol) can inhibit many 
CYP isoenzymes including CYP1A2, 
CYP2C9, CYP2D6, and CYP3A4 (Huang et 
al., 2010). The triterpene glycosides ap-
peared to be weak inhibitors (IC50 = 25-
100 M), while fukinolic acid and cimicifug-
ic acids A and B were more potent inhibitors 
(IC50 = 1.8-12.6 M) of all CYP isoen-
zymes studied. Therefore, these may have 
the potential to cause herbal drug interac-
tions (Huang et al., 2010). However, it needs 
to realize that evidence of in vitro CYP inhi-
bition, or that observed in animal models, 
may not exactly predict in vivo effects seen 
in humans (von Moltke et al., 1998). 
For some clinical studies, single-time 
point phenotypic metabolic ratios were used 
to determine whether long-term supplemen-
tation of black cohosh (Cimicifuga race-
mosa) extract affected CYP1A2, CYP2D6, 
CYP2E1, or CYP3A4 activity (Gurley et al., 
2005). Twelve healthy volunteers were ran-
domly assigned to receive black cohosh for 
28 days. Probe drug cocktails of midazolam 
and caffeine, followed 24 hours later by 
chlorzoxazone and debrisoquine, were ad-
ministered before (baseline) and at the end of 
supplementation. Presupplementation and 
postsupplementation phenotypic trait meas-
urements were determined for CYP3A4, 
CYP1A2, CYP2D6, and CYP2E1 by use of 
1-hydroxymidazo-lam/midazolam serum ra-
tios (1-hour sample), paraxanthine/caffeine 
serum ratios (6-hour sample), debrisoquine 
urinary recovery ratios (8-hour collection), 
and 6-hydroxychlorzoxazone/chlorzoxazone 
serum ratios (2-hour sample), respectively. 
Their results have shown that concomitant 
supplementation with black cohosh for 28 
days did not affect the activities of human 
CYP1A2, CYP2E1 and CYP3A4. Black co-
hosh did not cause a statistically significant 
alteration in the pharmacokinetics of midazo-
lam, indicating that black cohosh does not 
inhibit or induce CYP3A4. Thus, it is unlike-
ly that black cohosh will cause any clinically 
important herbal drug interactions with drugs 
metabolized by CYP3A4 (Gurley et al., 
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2005). However, black cohosh co-
administration produced a statistically signif-
icant decrease in CYP2D6 activity. As the 
magnitude of inhibitory effect of black co-
hosh on CYP2D6 was only approximately 
7% reduction, this may not be clinically rel-
evant (Gurley et al., 2005). The authors con-
cluded that black cohosh exhibited mild in-
hibition of CYP2D6; though, the clinical 
consequence of this effect remains uncertain. 
Later, the same group of investigators de-
termined the effects of black cohosh supple-
mentation on human CYP2D6 activity in vi-
vo using debrisoquine as a specific CYP2D6 
probe (Gurley et al., 2008a). The study was 
conducted together with other herbal sup-
plements in 16 healthy volunteers. Subjects 
were randomized to receive black cohosh 
supplement for 14 days. The CYP2D6 sub-
strate, debrisoquine (5 mg), was adminis-
tered before and at the end of supplementa-
tion. Pre- and post-supplementation pheno-
typic trait assessments were determined for 
CYP2D6 using 8- hour debrisoquine urinary 
recovery ratios. Comparisons of pre- and 
post-supplementation results revealed no 
significant effect of black cohosh on the ac-
tivity of CYP2D6 (Gurley et al., 2008a). 
Their results confirm previous clinical find-
ings that black cohosh (Gurley et al., 2005) 
is not a potent modulator of human CYP2D6 
in vivo. Thus, concomitant ingestion of black 
cohosh dietary supplements with drugs that 
are metabolized by CYP2D6 is not likely to 
cause clinically relevant herbal drug interac-
tions (Gurley et al., 2008a). In vitro studies 
have provided inconsistent results with one 
reporting high (Ho et al., 2011), one moder-
ate (Huang et al., 2010), and one no activity 
against CYP2D6 (Sevior et al., 2010). The 
discrepancy of in vitro and in vivo results 
again emphasizes caution in extrapolating 
findings of in vitro studies to clinical set-
tings. It also suggested that there is need for 
clinical investigations to be pursued to con-
firm the in vitro findings. With respect to 
CYP1A2, clinical studies have also shown 
that black cohosh supplementation did not 
significantly alter the activity of human 
CYP1A2 (Gurley et al., 2005). Therefore, 
clinically important herbal drug interactions 
are unlikely to occur when black cohosh die-
tary supplements are concomitantly taken 
with drugs which are metabolized by 
CYP1A2. 
With regard to effect of black cohosh on 
CYP3A4 activity, the in vivo results showing 
lack of effect were inconsistent with those 
found in an in vitro investigation which re-
ported an inhibitory effect of black cohosh 
on CYP3A4 activity (Huang et al., 2010). 
Moreover, it has been shown by an in vitro 
study that certain triterpene glycosides iso-
lated from black cohosh only weakly inhibit-
ed human CYP3A4 (Tsukamoto et al., 
2005). This is in agreement with in vivo data 
suggesting no clinically significant interac-
tions between black cohosh and CYP3A4 
(Gurley et al., 2005, 2006).  
Because hot flashes are the main indica-
tion for black cohosh use, women who expe-
rience this side effect of tamoxifen may de-
cide to use black cohosh as a presumably 
safe remedy. With this reason, Li et al. 
(2011) carried out an in vitro study using 
human liver microsomes to examine the ef-
fect of black cohosh supplements on the ac-
tivities of CYP enzymes involved in the me-
tabolism of tamoxifen. Pharmacological ac-
tivity of tamoxifen is dependent on the met-
abolic conversion into active metabolites by 
the action of CYP2D6 and CYP3A4. The 
objective of this study was to evaluate 
whether black cohosh extracts can inhibit 
formation of active tamoxifen metabolites 
and possibly reduce its clinical efficacy (Li 
et al., 2011). Using midazolam and dextro-
methorphan as probe substrates, ethanolic 
extract of black cohosh inhibited CYP3A4 
and CYP2D6 with IC50 values of 16.5 and 
50.1 µg/ml, respectively. The results of this 
study suggest that co-administration of black 
cohosh with tamoxifen might interfere with 
the clinical efficacy of this drug. However, 
additional clinical studies are required to un-
derstand the clinical significance of these in 
vitro results.  
EXCLI Journal 2014;13:869-896 – ISSN 1611-2156 
Received: June 26, 2014, accepted:July 28, 2014, published:August 20, 2014 
 
 
873 
Taken together, the effect of black co-
hosh extract on the activity of human CYP 
enzymes has been evaluated in a number of 
clinical trials. The existing data indicate that 
black cohosh is unlikely to affect the phar-
macokinetics of conventional drugs which 
are metabolized by CYP1A2, CYP2D6, 
CYP2E1 and CYP3A4. Moreover, 
Wanwimolruk and co-workers (Wanwimol-
ruk et al., 2009; Wanwimolruk and Pracha-
yasittikul, 2012) also found that seven dif-
ferent brands of commercial black cohosh 
products did not affect human CYP activities 
(CYP1A2 and CYP3A4) using an in vitro 
liver microsomal technique. Overall, black 
cohosh appears to present only minor risks in 
patients who are currently taking prescrip-
tion drugs. Nevertheless, additional studies 
in humans are desirable to establish the safe-
ty of concomitant use of black cohosh and 
conventional drugs. 
 
Ginseng 
Ginseng, one of the most popular herbal 
medicines, it has been used for thousands of 
years in various Asian countries. In the last 
twenty years, ginseng has also been in de-
mand in the Europe and United States as a 
dietary supplement (Qi et al., 2011). Today 
ginseng products rank among the most 
commonly used herbal products. Ginseng is 
the 5th best-selling herb in the United States 
(Goey et al., 2013). Asian ginseng (Panax 
ginseng) and American ginseng (Panax 
quinquefolius) are the two most well-known 
ginseng herbs worldwide (Qi et al., 2011). 
P. ginseng is one of the twenty most fre-
quently used complementary alternative 
medicines (CAM) in use by cancer patients 
(Werneke et al., 2004). P. ginseng is be-
lieved to possess anti-neoplastic, anti-aging, 
anti-oxidative and immunomodulatory ef-
fects (Goey et al., 2013). This herb is used 
for cancer prevention, erectile dysfunction, 
improved cognitive functions and enhanced 
physical functions (Goey et al., 2013). P. 
ginseng consists of ginsenosides and sapo-
genins, of which ginsenosides are the main 
components. Some notable differences be-
tween ginseng species exist in relation to the 
content and composition of ginsenosides, a 
factor that may be connected with a differen-
tial drug interaction potential. The recom-
mended daily dose of P. ginseng is 200 mg 
of standardized (i.e., 4 % total ginsenosides) 
extract. 
Several in vitro studies have investigated 
the effects of ginseng extracts or its extract 
constituents on CYP enzymes using various 
techniques. These in vitro studies have 
shown that ginseng has potential to inhibit 
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 
(Foster et al., 2003). However, these results 
have been mainly inconsistent and even con-
flicting (Hermann and von Richter, 2012; 
Shi and Klotz, 2012). Purified constituent 
kaempferol from ginseng displayed signifi-
cant inhibition of CYP3A4 activity, similarly 
P-gp (P-glycoprotein)-mediated efflux of 
ritonavir was also significantly inhibited (Pa-
tel et al., 2004). A major problem with the in 
vitro experiments is that the concentrations 
required to produce CYP inhibition or induc-
tion in vitro were often extremely high and 
unlikely to be attained in vivo following rec-
ommended doses of herbal products (An and 
Morris, 2010). Therefore, reliable predic-
tions of the in vivo relevance of these find-
ings are unachievable in practical terms. 
Even though there are so many in vitro 
studies have been conducted, clinical studies 
of pharmacokinetic ginseng drug interactions 
are limited. The majority of in vitro studies 
demonstrated that ginseng competitively in-
hibits human CYP3A4. Thus, the effect of 
ginseng would have on CYP3A4 could be 
anticipated in the clinical studies. A number 
of clinical studies did find significant inhibi-
tion of CYP3A4 by ginseng when they used 
midazolam as a typical marker for human 
CYP3A4 enzyme. The effect of P. ginseng 
on the activities of CYP enzymes was inves-
tigated in a single time-point phenotyping 
study. Caffeine was used as a specific probe 
for CYP1A2, debrisoquine for CYP2D6, 
chlorzoxazone for CYP2E1, and midazolam 
for CYP3A4. The ginseng extract was given 
at a dose of 500 mg (three times daily, stand-
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ardized to 5 % ginsenosides) for 28 days as a 
pretreatment. They found no significant ef-
fects of P. ginseng on the activities of all 
CYP enzyme studied including CYP1A2, 
CYP2D6, CYP2E1 and CYP3A4 (Gurley et 
al., 2002). A similar study was conducted in 
healthy elderly subjects, using the same dose 
of P. ginseng product, and treatment dura-
tion, as well as the same CYP probe drugs, 
P. ginseng supplementation had no signifi-
cant effects on any CYP enzyme activity 
(Gurley et al., 2005). Presumably, the inhibi-
tory potency of ginsenosides is too low to 
produce significant clinical CYP3A4 inhibi-
tion (Goey et al., 2013). High plasma con-
centrations of ginsenosides are required for 
inhibition of CYP3A4, as the IC50 values of 
many ginsenosides have shown to be more 
than 1000 times greater than the IC50 value 
of the potent CYP3A4 inhibitor ketocona-
zole (Henderson et al., 1999). Later reports 
by Anderson et al. (2003) supported the find-
ings of Gurley and co-workers (Gurley et al., 
2002, 2005) in respect to lack of ginseng on 
the activity of human CYP3A4. In Anderson 
and colleagues’ study (Anderson et al., 
2003), 100 mg of P. ginseng extract (stand-
ardized to 4 % ginsenosides) were given 
twice a day for 14 days to 20 healthy volun-
teers. The urinary 6-β-hydroxycortisol/corti-
sol ratio, a marker of CYP3A enzyme induc-
tion was found to remain unchanged after the 
ginseng supplementation. These results indi-
cate that P. ginseng, at recommended doses, 
does not confer significant CYP3A induction 
in vivo (Anderson et al., 2003). 
However, one clinical study, reported 
that P. ginseng caused a significant induction 
of CYP3A4 (Malati et al., 2012). Intake of 
500 mg P. ginseng (twice daily for 28 days, 
standardized to 5 % ginsenosides) by healthy 
volunteers significantly decrease (34 %) the 
AUC of oral midazolam. This suggested that 
long term ginseng supplementation caused 
an induction of CYP3A4 enzyme. Remarka-
bly, this significant induction of CYP3A4 
differed from the observations found in the 
other two studies with midazolam, despite a 
similar composition of the P. ginseng prod-
uct (500 mg extract, standardized to 5 % gin-
senosides) and a lower dosing frequency. 
Perhaps, differences in determinations of 
CYP3A4 activity account for these conflict-
ing results. A one-hour post dose serum con-
centration ratio of 1-hydroxymidazolam/ 
midazolam was the primary method used in 
studies indicating no apparent interaction 
between P. ginseng and midazolam (Gurley 
et al., 2002, 2005). Whereas midazolam 
AUC was assessed in the clinical study sug-
gesting CYP3A4 induction by P. ginseng 
(Malati et al., 2012). It has been noted that 
determination of the AUC of midazolam is 
more accurate to assess CYP3A4 activity 
than a single sample collection of midazolam 
(Penzak et al., 2008). Thus, it is possible that 
a CYP3A4 induction by P. ginseng may 
have failed to notice in the studies with a 
single sampling strategy (Goey et al., 2013). 
The effects of American ginseng (Panax 
quinquefolius) on the pharmacokinetics of 
the HIV protease inhibitor and sensitive 
CYP3A4 substrate indinavir were investigat-
ed in 14 healthy adults (Andrade et al., 
2008). The HIV protease inhibitor, indinavir 
using 800 mg doses was administered three 
times a day, either alone or together with 
1.0 g doses of American ginseng three times 
daily over 2 weeks period (dried whole root 
500 mg capsules). The results have shown 
that American ginseng did not affect the 
pharmacokinetics of the CYP3A4 substrate 
indinavir. This suggests that American gin-
seng does not cause any appreciable 
CYP3A4 induction or inhibition. 
The influence of a standardized Siberian 
ginseng (Eleutherococcus senticosus) extract 
on the activity of cytochrome P450 CYP2D6 
and CYP3A4 was assessed in 12 healthy 
subjects (Donovan et al., 2003). Probe sub-
strates dextromethorphan (CYP2D6 activity) 
and alprazolam (CYP3A4 activity) were ad-
ministered orally at baseline and again fol-
lowing treatment with Siberian ginseng (1 x 
485 mg twice daily) for 14 days. Urinary 
concentrations of dextromethorphan and 
dextorphan were quantified, and dextrome-
thorphan metabolic ratios were determined at 
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baseline and after Siberian ginseng treat-
ment. Likewise, plasma samples were col-
lected (0–60 h) for alprazolam pharmacoki-
netics at baseline and after Siberian ginseng 
treatment to assess effects on CYP3A4 activ-
ity. There were no statistically significant 
differences between pre- and post-Siberian 
ginseng treatment in term of urinary dextro-
methorphan/dextrorphan metabolic ratios. 
This indicates a lack of Siberian ginseng ef-
fect on CYP2D6 enzyme activity. For alpra-
zolam results, there also were no significant 
differences in plasma concentrations and de-
rived pharmacokinetic parameters (Cmax, 
tmax, AUC, t1/2). These results indicate that 
Siberian ginseng does not induce or inhibit 
CYP3A4 enzyme. Their results are in line 
with the outcomes reported for P. ginseng 
preparations as described above. These also 
suggest that standardized extracts of Siberian 
ginseng at generally recommended doses for 
over-the-counter use are unlikely to affect 
the activity of CYP2D6 or CYP3A4. There 
appears to be little likelihood of significant 
herbal drug interactions between Siberian 
ginseng and drugs predominantly metabo-
lized by CYP2D6 or CYP3A4 isoforms (Do-
novan et al., 2003). 
The effects of P. ginseng on the pharma-
cokinetics and pharmacodynamics of warfa-
rin were examined in 12 healthy subjects 
(Jiang et al., 2004). A single 25-mg dose of 
warfarin (Coumadin™, 5 × 5-mg tablets) 
was administered to each subject with and 
without pretreatment with multiple doses of 
Asian ginseng for 1 week (Korean ginseng, 
each capsule containing extract equivalent to 
0.5 g Panax ginseng root and 8.93 mg gin-
senosides as ginsenoside Rg1; 2 × 0.5-g cap-
sules, three times daily). Dosing of ginseng 
was continued for a further 1 week after war-
farin administration. The bioanalytics com-
prised enantiomer-selective quantification of 
S-warfarin, which is predominantly metabo-
lized to S-7-hydroxy-warfarin by CYP2C9, 
and R-warfarin, which is metabolized by 
CYP3A4 and CYP1A2. This allows for a 
separate systematic assessment of any poten-
tial alteration of these metabolic pathways by 
concomitant P. ginseng treatment. The re-
sults have shown that P. ginseng treatment 
did not affect the pharmacokinetics and 
clearance of both warfarin enantiomers in 
human subjects. This implies that ginseng 
has no appreciable effect on the activity of 
CYP1A2, CYP3A4, or CYP2C9 in healthy 
subjects. Pharmacodynamic endpoints of 
warfarin were also evaluated in this study. It 
was shown that P. ginseng did not signifi-
cantly alter blood coagulation (i.e., Interna-
tional normalized ratio, INR) outcomes and 
platelet aggregation (Jiang et al., 2004). 
The lack of effect by ginseng on the 
pharmacokinetics of warfarin was largely 
ratified by the results obtained by the same 
group of investigators (Jiang et al., 2006). 
This study employed a similar study design 
for investigating warfarin interactions and 
was a comparable subject size (12 healthy 
male subjects). Similar as in the previous 
study, dosing of the herbal product was the 
same and continued for a further week after 
warfarin administration. The results demon-
strated that concomitant administration of 
ginseng with warfarin did not affect the 
pharmacokinetics or pharmacodynamics of 
either S-warfarin or R-warfarin (Jiang et al., 
2006). The pharmacodynamic endpoints of 
warfarin including International normalized 
ratio (INR) and platelet aggregation were not 
altered by treatment with ginseng. Therefore, 
these observations confirmed the findings 
resulting from previous study (Jiang et al., 
2004).  
A randomized, double-blind, placebo-
controlled trial was conducted in healthy 
adult subjects, to evaluate the interactions 
between American ginseng and warfarin 
(Yuan et al., 2004). In this 4-week study, 20 
subjects received warfarin for 3 days during 
weeks 1 and 4. Beginning in week 2, sub-
jects were assigned to receive either Ameri-
can ginseng (P. quinquefolius, 0.5 g cap-
sules) or placebo. INR and plasma warfarin 
level were determined. The peak INR was 
shown to decrease statistically significantly 
after 2 weeks of ginseng administration 
compared with placebo. The INR area under 
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the curve (AUC), peak plasma warfarin lev-
el, and warfarin AUC were also significantly 
reduced in the ginseng group as compared 
with the placebo group. The average group 
results, however, have to be interpreted with 
caution, because the INR data in the ginseng 
group were mainly pushed by one outlier 
subject exhibiting a high baseline INR (1.32) 
and an unusually increased peak INR after 
warfarin administration on day 4. After gin-
seng co-administration, the peak INR of this 
patient declined remarkably from 5.16 to 
2.75, and the corresponding AUC of INR 
decreased from 17.5 to 11.1. Even though 
the authors pointed out that the results of 
their study remain statistically significant, 
when this outlier patient is excluded from 
analysis, it becomes apparent, that parallel 
group studies of such a small sample size are 
difficult to interpret (Hermann and von Rich-
ter, 2012). 
Overall, the clinical studies on the effects 
of ginseng on the activity of human CYP 
yielded consistency of data which convinc-
ingly suggest that at recommended therapeu-
tic doses, ginseng products have no signifi-
cant effect on CYP enzyme either inhibitory 
or induction properties. Therefore, it is un-
likely that herbal drug interactions will occur 
via CYP metabolism when the patients take 
ginseng products concomitantly with pre-
scription drugs. Furthermore, the published 
data from clinical studies on ginseng and 
warfarin interaction suggest that high repeat-
ed doses of P. ginseng (over 1 week) did not 
significantly change the pharmacokinetics or 
pharmacodynamics of 25 mg warfarin single 
doses in healthy adults (Greenblatt and von 
Moltke, 2005; Jiang et al., 2004). On the 
other hand, Yuan et al. (2004) conducted a 
small parallel group study in healthy subjects 
which revealed conflicting findings. They 
employed a different warfarin dosage regi-
men (5 mg warfarin daily on 3 consecutive 
days) and a 2-week treatment with American 
ginseng (P. quinquefolius) at the high end of 
the recommended dose range. Their finding 
suggests American ginseng may reduce war-
farin exposure (i.e., increases warfarin clear-
ance), thus diminishing the anticoagulant 
effect of warfarin to a modest extent (Yuan 
et al., 2004). The differences in the outcome 
of these studies could be either due to differ-
ent properties of Asian ginseng (P. ginseng) 
and American ginseng (P. quinquefolius) 
products, or differences in the study designs 
(1-week vs. 2-week treatments). Alternative-
ly, the differences could be due to the limita-
tions of the small parallel group study which 
was apparently highly influenced by an out-
lier subject (Hermann and von Richter, 2012; 
Yuan et al., 2004). 
 
Grape seed extract 
Grapes (Vitis vinifera) are one of the 
most consumed fruit in the world and grape 
seed extract is one of the top-selling herbal 
dietary supplements in the United States 
(Choi et al., 2011; Sparreboom et al., 2004). 
Polyphenolic compounds including flavo-
noids and resveratrol are well-known com-
ponents of grapes. Approximately 90-95 % 
of grape polyphenols exist in grape seeds 
and grape skin. Most of the grape seed poly-
phenols are quite different from tea polyphe-
nols. Grape seed polyphenols are mainly rich 
in polymers (e.g., procyanidins or proantho-
cyanidins) whereas most tea polyphenols are 
monomers, such as catechins. Various natu-
rally occurring polyphenol antioxidants are 
known to be present in grape seeds common-
ly known as procyanidins (Bartolome et al., 
1996; Singleton, 1992). Commercial prepa-
rations of grape seed polyphenols, widely 
referred to as “grape seed extract”, are stand-
ardized to contain 95 % procyanidins and are 
marketed in the USA as a dietary supple-
ment. The consumer interest in grape seed 
extract has been mainly due to the high con-
tent of antioxidants in the form of procya-
nidins in this extract (Kaur et al., 2009). 
Many studies have shown that grape seed 
procyanidins possess anti-inflammatory, an-
ti-arthritic and anti-allergic activities and 
prevent heart attack and skin aging (Bagchi 
et al., 1998; Maffei et al., 1996). Grape seed 
extract has been demonstrated to exhibit an-
tioxidant and anticancer activities in both in 
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vitro and in vivo models (Bagchi et al., 2002; 
Kaur et al., 2009; Sharma et al., 2004; Ye et 
al., 1999). There are a number of studies 
suggesting that grape seed extract could be a 
potential cancer chemopreventive agent 
against various cancers in animal models 
(Bomser et al., 1999; Zhao et al., 1999). An 
epidemiological study has shown that in-
creased consumption of grapes is associated 
with reduced cancer risk (Kaur et al., 2009; 
Zheng et al., 1993). Overall, completed stud-
ies from various scientific groups conclude 
that both grapes and grape-based products 
are excellent sources of various anticancer 
agents and their regular consumption should 
thus be beneficial to the general population 
(Kaur et al., 2009). 
Wine consumption has been reported to 
have many beneficial health effects, and 
wine may also be a source of grape seed pro-
cyanidins (Halpern et al., 1998; Soleas et al., 
1997). Epidemiological studies have strongly 
suggested that light to moderate wine con-
sumption is associated with a reduced inci-
dence of mortality and morbidity from coro-
nary heart disease more than the consump-
tion of other alcoholic beverages. This gave 
rise to what is now popularly known as the 
“French Paradox” (Renaud and De Lorgeril, 
1992).  
Resveratrol appeared to be an important 
constituent in grape seed extract. It has been 
studied extensively and evidence points to 
the potential of resveratrol for human health 
improvement (Choi et al., 2011). Red wine 
solids and resveratrol were investigated for 
their ability to alter human CYP activity. In 
vitro studies have shown that both red wine 
solids and resveratrol were irreversible 
(mechanism-based) inhibitors of CYP3A4 
and non-competitive reversible inhibitors for 
CYP2E1 in microsomes from rat liver and 
cDNA-expressed CYP human liver cells 
(Chan and Delucchi, 2000; Piver et al., 
2001). Resveratrol is an electron-rich mole-
cule with two aromatic benzene rings linked 
by an ethylene bridge. Aromatic hydroxyla-
tion and epoxidation of resveratrol mediated 
by CYP3A4 possibly produce a reactive p-
benzoquinonemethide metabolite which is 
highly capable of covalently binding to 
CYP3A4 enzyme. Consequently, this leads 
to inactivation of CYP3A4 (i.e., mechanism-
based inhibition), and potential drug interac-
tions (Rodríguez-Fragoso et al., 2011). Inter-
estingly, inactivation of CYP3A4 by a range 
of red wines did not correlate with the con-
tent of resveratrol (Chan and Delucchi, 
2000). 
CYP1A1 and CYP1B1 have been shown 
to act as bioactivating enzymes for activation 
of carcinogens, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) and benzo[a]-
pyrene (Song et al., 2010). An in vitro find-
ing revealed that grape seed extract was able 
to reduce CYP1A1 and CYP1B1 contents in 
breast cells exposed to NNK and ben-
zo[a]pyrene (Song et al., 2010). It is possible 
that reduction of CYP1A1 and CYP1B1 con-
tents may contribute to the ability of grape 
seed extract to suppress cellular acquisition 
of cancer-related properties induced by NNK 
and benzo[a]pyrene.  
Chow and co-workers (Chow et al., 
2010) carried out a clinical study to deter-
mine the effect of pharmacologic doses of 
resveratrol on drug- and carcinogen-
metabolizing enzymes. Forty-two healthy 
volunteers underwent baseline assessment of 
CYP and phase II detoxification enzymes. 
CYP1A2, CYP2D6, CYP2C9, and CYP3A4 
enzyme activities were assessed by the me-
tabolism of caffeine, dextromethorphan, 
losartan, and buspirone, respectively. After 
the baseline evaluation, study participants 
received a pretreatment with 1 g of resvera-
trol once daily for 4 weeks. Enzyme assess-
ment was repeated upon pretreatment com-
pletion. They found that 4 weeks of daily 
resveratrol administration resulted in a 16 % 
decrease in the caffeine/paraxanthine meta-
bolic ratio. This suggests resveratrol pre-
treatment caused an induction of human 
CYP1A2 activity. Many environmental car-
cinogens, such as polycyclic aromatic hydro-
carbons, are generally thought to be activated 
by the CYP1A and CYP1B subfamilies to 
form genotoxic epoxide metabolites, which 
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can bind to DNA, forming DNA adducts. 
Therefore, inhibition of these enzymes is 
thought to be an important mechanism in the 
prevention of carcinogenesis. Resveratrol 
pretreatment also resulted in 33 %, 70 %, 
and 171 % increases in buspirone AUC, 
metabolic ratio of dextromethorphan to dex-
trorphan, and metabolic ratio of losartan to 
E3174, respectively. These changes implied 
that resveratrol inhibited the activities of 
CYP3A4, CYP2D6, and CYP2C9, respec-
tively (Chow et al., 2010). Among these 
CYP enzymes, CYP3A4 metabolizes the 
great majority of drugs, including immuno-
suppressive drugs for transplant patients, 
HIV protease inhibitors, cholesterol-
lowering statin drugs, and chemotherapeu-
tics. Inhibition of CYP3A4 would result in 
elevation of the systemic blood levels of 
drugs metabolized by this CYP3A4 isozyme, 
which could lead to increased drug toxicity 
(Chow et al., 2010). CYP2D6 is accountable 
for converting tamoxifen to the potent anti-
estrogen endoxifen. Studies have shown that 
individuals with decreased CYP2D6 metabo-
lism due to genetic variations or enzyme in-
hibition have reduced plasma endoxifen con-
centration and increased risk of breast cancer 
relapse (Goetz et al., 2007; Jin et al., 2005). 
It is possible that resveratrol could reduce 
the formation of endoxifen, so affecting the 
chemopreventive or anticancer activity of 
tamoxifen. CYP2C9 is involved in the meta-
bolic clearance of a wide variety of therapeu-
tic drugs, including many non-steroidal anti-
inflammatory drugs, cyclooxygenase-2 in-
hibitors, oral anticoagulants, and oral hypo-
glycemics. This raises the question of 
whether resveratrol would decrease the 
clearance of these drugs, probably intensify-
ing the toxicity of these drugs (Chow et al., 
2010). The authors conclude that resveratrol 
can modify enzyme systems implicated in 
activation and detoxification of carcinogens. 
This may be one mechanism by which 
resveratrol prevents carcinogenesis. Howev-
er, pharmacologic doses of resveratrol could 
possibly directly enhanced adverse drug re-
actions or alter drug efficacy due to inhibi-
tion or induction of certain CYPs. Further 
clinical development of resveratrol for can-
cer prevention should reflect evaluation of 
lower doses of resveratrol to minimize ad-
verse metabolic drug interactions (Chow et 
al., 2010). However, these speculations of 
consequence of resveratrol on drug efficacy 
and drug interactions have not been testified 
by clinical studies. It also needed to be cau-
tioned that with these speculations as alt-
hough the changes produced by resveratrol 
were statistically significant, but are relative-
ly small according to current FDA drug in-
teraction guideline recommendations (US 
Department of Health and Human Services/ 
Food and Drug Administration Center for 
Drug Evaluation and Research, 2012). 
In addition, nine commercial brands of 
grape seed extract dietary supplements were 
tested in vitro to determine whether grape 
seed extracts can inhibit the activity of hu-
man CYP3A4 (Wanwimolruk et al., 2009). 
Their results have shown that grape seed ex-
tract had considerably little effect on 
CYP3A4 activity, ranging from 0 % (no ef-
fect) to 26.8 % inhibition. Thus, this suggests 
that the inhibitory effect on CYP3A4 caused 
by grape seed extract dietary supplements 
was mild but the effect was variable depend-
ing on the brand of the grape seed extract 
products. This magnitude of CYP3A4 inhibi-
tion by grape seed extract is rather small as 
compared with inter-individual variation of 
human CYP3A4 activity (Watkins 1994; 
Wrighton et al., 1993; Zhang et al., 1997). 
Therefore, it is doubtful that adverse herbal 
drug interactions will occur when grape seed 
extract dietary supplements are concomitant-
ly taken with prescription drugs that are me-
tabolized by CYP3A4. 
 
Green tea 
Green tea (Camellia sinensis, Family 
Theaceae) is made from the leaves of the 
plant Camellia sinensis Thaecae, and has 
been part of Eastern medicine for millennia. 
Tea was first used as a medicinal herb in an-
cient China and now tea is a widely con-
sumed beverage. Second only to water, green 
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tea in particular, is the most popular bever-
age in the world, especially Asian countries. 
The potential preventive activities of green 
tea against cancer and cardiovascular diseas-
es have been thoroughly investigated during 
the past 25 years (Yang and Pan, 2012). In 
addition to conventional green tea infusion, 
concentrated green tea extract in liquid or 
capsule formulations have become the vehi-
cle of choice for healthy individuals seeking 
to increase their overall health. One of ex-
ample is those being marketed for weight 
reduction. Other health claims for green tea, 
such as its supposed cardiovascular protec-
tion and anti-cancer effects (see critical re-
views - Deka and Vita, 2011; Lambert et al., 
2007; Moore et al., 2009; Sturgeon et al., 
2009; Yang and Wang, 2011; Yang et al., 
2011), have further contributed to the in-
creasingly widespread consumption of large 
dosages of green tea extract. Cancer patients 
in particular may be desirous to self-
medicate with such herbal supplements in-
cluding green tea, in hopes of suspending the 
progression of their disease and/or ease the 
adverse effects associated with conventional 
chemotherapy. Epidemiological studies re-
veal that consumption of green tea reduces 
cancer risk (Dreosti et al., 1997; Katiyar and 
Mukhtar, 1996; Hayat et al., 2013). These 
data have been proved by the findings of 
numerous preclinical studies showing that 
green and black tea are potent inhibitors of 
carcinogenesis in various rodent models, in-
cluding models for cancers of the skin, lung, 
esophagus, stomach, liver, duodenum, small 
intestine, pancreas, colon-rectum, and 
mammary gland (Bode and Dong, 2009; 
Yang et al., 1997, 2002). 
The typical constituents in green tea are 
tea polyphenols known as catechins, caffeine 
and a unique amino acid (theanine). The 
health effects of the tea seem to be due to 
catechins which represent 30-45 % of solid 
green tea extract and have anti-cancer, anti-
metastatic, anti-inflammatory, anti-anthrax 
lethal factor, and vasculoprotective proper-
ties (Schönthal, 2011; Yang and Pan, 2012). 
Like many drugs, these tea chemicals are 
absorbed, metabolized and eliminated. 
Therefore, potential interactions between tea 
constituents and drugs as competitive sub-
strates or inhibitors can be anticipated. Tea 
catechins may perhaps directly bind to drugs 
and reduce their absorption, bioavailability 
and their biological activities. Tea catechins 
may also increase or decrease the activities 
of drug-metabolizing enzymes and drug 
transporters (Yang and Pan, 2012). 
There are numerous in vitro data on the 
effects of green tea and green tea extract on 
the metabolism of drugs and activities of 
CYP. Many of these studies were in vitro 
studies and some were conducted in animals. 
As this review is aimed to provide infor-
mation on herbal drug interactions in hu-
mans, these studies are not relevant and 
therefore are not included. One of important 
clinical studies is performed by Donovan et 
al. (2004) who determined the effect of de-
caffeinated green tea extract on the disposi-
tion of dextromethorphan (a CYP2D6 sub-
strate) and alprazolam (a CYP3A4 substrate) 
in healthy volunteers. After 14-day pretreat-
ment with two capsules twice daily of decaf-
feinated super green tea extract (containing 
211 ± 25 mg of green tea catechins/capsule), 
the subjects received a single 30 mg dose of 
dextromethorphan and 2 mg of alprazolam. 
The results derived from the study revealed 
no significant alterations in the Cmax, tmax, 
AUC and elimination half-life (Donovan et 
al., 2004). The authors suggested that decaf-
feinated green tea is unlikely to alter the dis-
position of medications primarily dependent 
on the CYP2D6 or CYP3A4 pathways of 
metabolism. 
Chow and colleagues (Chow et al., 2006) 
conducted a clinical study to determine the 
effect of repeated green tea catechin admin-
istration on human CYP enzyme activities. 
After refraining from tea or tea-related prod-
ucts for or 4 weeks, 42 healthy volunteers 
received a cocktail of CYP metabolic probe 
drugs, including caffeine, dextromethorphan, 
losartan, and buspirone for assessing the ac-
tivity of CYP1A2, CYP2D6, CYP2C9, and 
CYP3A4, respectively. Blood and urine 
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samples before and 8 h after probe drug ad-
ministration were collected to determine par-
ent drug and metabolite concentrations for 
measurements of baseline CYP enzyme ac-
tivities. After pretreatment with four cap-
sules of green tea catechin extract (contains 
800 mg epigallocatechin gallate [EGCG]) 
daily for 4 weeks, a single dose of a probe 
drug was coadministered to the volunteers 
and blood samples were collected in the 
same manner. Their results have demonstrat-
ed that 4-week pretreatment with green tea 
catechin did not alter the activities of 
CYP1A2, CYP12D6, and CYP12C9. How-
ever, green tea pretreatment resulted in a 
significant increase (20 %) in the AUC of 
buspirone suggesting there was a small inhi-
bition of CYP3A4 activity caused by green 
tea catechin. Of interest, the authors estimat-
ed the daily administration of 800 mg of 
EGCG (i.e. four of the capsules) to be equiv-
alent to the EGCG content of 8–16 cups of 
green tea (Chow et al., 2006). Because no 
clinically relevant changes in CYP pheno-
typic indices were observed at the selected 
dose and dosing condition, potential for drug 
interactions is unlikely with regular green tea 
consumption at lower catechin content. The 
authors concluded that repeated green tea 
catechin administration is not expected to 
result in clinically significant effects on the 
disposition of drugs metabolized by these 
CYP enzymes. In addition, the discrepancy 
in the findings on CYP3A4 observed by 
Chow et al. (2006) and Donovan et al. 
(2004) might be related to different sample 
sizes used in these studies. With a sample 
size of 11 in Donovan et al. (2004) study, it 
may not be powerful enough to detect small 
changes in CYP3A4 enzyme activity. The 
lack of effect on CYP3A4 activity could also 
be due to disparity in the sensitivity of dif-
ferent probe drugs to enzyme modulations 
because the same CYP3A4 inhibitors led to 
greater changes in AUC of buspirone than 
that of midazolam AUC (Bjornsson et al., 
2003; Schönthal, 2011). In our opinion, the 
inconsistency of findings may also be due to 
variability in total phenol and catechin con-
tents in green tea products used. It has been 
shown that there is considerable variability 
both in total phenol and catechin content (as 
well as caffeine content), depending on the 
brand of product, the region the tea was 
grown, the age of the leaves, the manufactur-
ing process conditions, infusion time, etc. 
(Astill et al., 2001; Khokhar and Magnusdot-
tir, 2002). 
Even though dried green tea leaves have 
been found to contain substantial amounts of 
vitamin K, however brewed green tea is 
normally not regarded as a significant source 
of the vitamin. However, large amounts of 
brewed green tea might reduce the anticoag-
ulant effect of warfarin (Heck et al., 2000). A 
44-year-old patient with a mechanical heart 
valve received warfarin therapy. The INR of 
this patient decreased markedly when he 
started drinking large amounts of brewed 
green tea (Taylor and Wilt, 1999). The pa-
tient turned up to the outpatient clinic with 
an INR of 1.37; his INR 22 days prior to this 
visit had been 3.79. The patient was unable 
to be reached until his return visit to the clin-
ic one month later, at which time his INR 
was 1.14. In an interview, the patient dis-
closed that he had started drinking 0.5-
1 gallon of brewed green tea daily about one 
week before the INR measurement of 1.37. 
There were no other recognizable causes of 
the remarkable decrease in the INR, includ-
ing changes in the patient’s medications, die-
tary intake, medication compliance, or medi-
cal conditions. A substantial drop in the INR 
would not typically be expected to result 
from regular consumption of moderate 
amounts of brewed green tea. Generally it is 
not necessary to advise patients getting war-
farin therapy to avoid green tea. Neverthe-
less, patients should be advised that large 
quantities of green tea may diminish the ef-
fectiveness of warfarin therapy (Heck et al., 
2000). 
Collectively, a number of studies re-
vealed the lack of effect of regular green tree 
consumption on the activities of human CYP 
enzymes including CYP1A2, CYP2C9, 
CYP2D6, and CYP3A4. Thus it is suggested 
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that drinking green tree or taking green tree 
extract as dietary supplements, at regular 
doses is unlikely to cause adverse drug inter-
actions with prescription drugs which are 
metabolized by these CYP enzymes. Alt-
hough a clinical study by Chow et al. (2006) 
highlighted the 4-week green tea extract me-
diated interaction with the CYP3A4-
metabolized drug, buspirone, the underlined 
mechanism of this interaction remains to be 
clarified. The variability between subjects 
suggested a possible pharmacogenetic pre-
disposition for green tea interactions. While 
awaiting further information and experi-
ments in humans, consumption of green tea 
and green tea extract should be monitored in 
patients receiving drugs metabolized by 
CYP3A4. Also patients who are prescribed 
drugs with a narrow therapeutic index such 
as warfarin should be cautioned about the 
effects green tea consumption may have on 
their treatment.  
 
Kava (Piper methysticum)  
Kava (Piper methysticum G Forst, Fami-
ly Piperaceae) is a shrubby plant indigenous 
to the South Pacific Islands, including Ha-
waii, Vanuatu, Polynesia, Melanesia and 
some parts of Micronesia. An extract from 
the rhizome and roots of kava have been 
used in the South Pacific as part of a recrea-
tional and ceremonial drink for 2000 years 
(Lebot et al., 1997). The commercial prod-
ucts are prepared from dried rhizomes of the 
kava plant, and the more contemporary dos-
age form it is a capsule, which usually con-
tain a standard 30 % of kavalactones (Za-
doyan and Fuhr, 2012). The constituents of 
kava extract are kavalactones, kawain, me-
thysticin, dihydromethysticin, desmethoxy-
yangonin, and dihydrokawain (Shord et al., 
2009). In Western countries, dietary supple-
ments containing kava are used for the 
treatment of anxiety and to relieve stress and 
tension, as well as for sleeplessness and 
menopausal symptoms (Teschke, 2010; 
Teschke and Schulze, 2010). The available 
evidence suggests that kava extracts are su-
perior to placebo for treating patients with 
anxiety disorders (Sarris et al., 2011). Kava-
containing products remain popular in the 
United States and continue to be sold in 
health food stores and ethnic markets. How-
ever, it was banned in many Western coun-
tries such as UK, Germany, France, Switzer-
land, Australia, and Canada, following re-
ports of suspected hepatotoxicity (Capasso et 
al., 2003; Lim et al., 2007). 
Although the alteration in CYP enzyme 
activity is one of the important causes of 
herbal drug interactions, there were only a 
few human studies existing to evaluate the 
clinical relevance of potential CYP-mediated 
interactions caused by kava. In an early 
study, single-time point phenotypic metabol-
ic ratios were employed to determine wheth-
er long-term supplementation of kava (Piper 
methysticum) extract affected CYP1A2, 
CYP2D6, CYP2E1, or CYP3A4 activity 
(Gurley et al., 2005). Twelve healthy sub-
jects were randomly assigned to receive kava 
for 28 days. Probe drug cocktails of midazo-
lam (CYP3A4) and caffeine (CYP1A2), fol-
lowed 24 hours later by chlorzoxazone 
(CYP2E1) and debrisoquine (CYP2D6), 
were administered before (baseline) and at 
the end of supplementation. Pre-
supplementation and post-supplementation 
phenotypic trait assessments were deter-
mined for CYP3A4, CYP1A2, CYP2E1, and 
CYP2D6 as described previously (Gurley et 
al., 2002). Comparisons of pre-supplement-
ation and post-supplementation phenotypic 
ratios revealed that kava significantly re-
duced the serum ratio of 6-hydrochlor-
zoxazone to chlorzoxazone, a measure of 
CYP2E1 catalytic activity, by 40 %. This 
indicates that kava supplementation caused a 
considerable inhibition of human CYP2E1 
enzyme activity (Gurley et al., 2005). It may 
suggest that taking kava concomitantly with 
drugs that are metabolized by CYP2E1 is 
likely to cause an herbal drug interaction. On 
the other hand, kava supplementation had no 
considerable effect on the activity of other 
CYP studied, i.e., CYP1A2, CYP2D6, and 
CYP3A4 (Gurley et al., 2005). 
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The potential effect of kava on human 
CYP3A4 activity was investigated by the 
same group of researchers (Gurley et al., 
2008a). In this randomized trial, 16 healthy 
volunteers were randomly assigned to re-
ceive either goldenseal or kava for 14 days. 
Each supplementation phase was followed 
by a 30-day washout period. Midazolam was 
used as a CYP3A4 probe and was orally ad-
ministered before and after each phase, and 
pharmacokinetic parameters were deter-
mined. The results showed that kava did not 
alter the pharmacokinetics of midazolam 
(CYP3A4), indicating that the concomitant 
ingestion of kava does not inhibit CYP3A4 
activity. This supports the earlier study con-
ducted by these investigators (Gurley et al., 
2005), finding lack of effect of kava on hu-
man CYP3A4 activity. This evidence sug-
gests that herbal drug interactions are unlike-
ly to occur when the patients concomitantly 
take kava dietary supplements with CYP3A4 
substrate drugs. 
Regarding CYP2D6 which is an im-
portant CYP isoform as it accounts for the 
metabolism of approximately 30 % of all 
medications, there were few in vivo studies 
have assessed the effects of kava on 
CYP2D6 activity. Six herbal extracts includ-
ing kava were evaluated in three separate 
studies, each incorporating 16 healthy volun-
teers (Gurley et al., 2008b). Subjects were 
randomized to receive a standardized herbal 
extract (including kava) for 14 days on sepa-
rate occasions. The CYP2D6 probe, debriso-
quine (5 mg), was administered before and at 
the end of supplementation. Pre- and post-
supplementation phenotypic trait measure-
ments were assessed for CYP2D6 using 8-
hour debrisoquine urinary recovery ratios. 
Comparisons of pre- and post-supplement-
ation results revealed no significant inhibi-
tion of CYP2D6 after post-supplementation 
of kava extract. This suggests that kava does 
not notably change the activity of human 
CYP2D6. Accordingly, it is doubtful that 
adverse herbal drug interactions would result 
with concomitant ingestion of kava supple-
ments and drugs that are metabolized by 
CYP2D6 (Gurley et al., 2008b). 
Of interest, kava may also inhibit human 
CYP1A2 activity based on evidence ob-
tained from a clinical study (Russmann et al., 
2005). These investigators aimed to deter-
mine whether clinically relevant interactions 
were to be anticipated from the consumption 
of the aqueous extract of kava root (Piper 
methysticum), which is common in the South 
Pacific. This study was conducted in 6 New 
Caledonian healthy subjects who consumed 
traditional aqueous kava extract regularly for 
more than 6 years. It was estimated that they 
drank approximately 7-27 g of kavalactones 
per week up to the beginning of the study. 
The participants were requested to stop kava 
consumption for 30 days without any other 
change in their lifestyle including diet, 
smoking, and medication and to undergo 2 
sessions of CYP phenotyping by using a sin-
gle time point phenotypic ratio method as 
described previously (Gurley et al., 2002). 
Metabolic ratios for 5 different probe drugs 
including caffeine (CYP1A2), mephenytoin 
(CYP2C19), debrisoquine (CYP2D6), chlor-
zoxazone (CYP2E1), and midazolam 
(CYP3A4) were determined before and after 
a 30-day complete abstinence from kava. 
Their results have shown that kava consump-
tion had no significant effect on the activities 
of CYP2C19, CYP2D6, CYP2E1 and 
CYP3A4. These results with CYP2C19, 
CYP2D6 and CYP3A4, are in agreement 
with previous reports cited by other re-
searchers (Gurley et al., 2005, 2008a, b). 
However, with respect to CYP2E1 finding, 
lack of effect by kava on CYP2E1 is in con-
trast with previous data obtained by Gurley 
et al. (2005) who reported that kava supple-
mentation caused a considerable inhibition 
of human CYP2E1 enzyme. Russmann et al. 
(2005) found interesting results regarding the 
potential interaction of kava and CYP1A2. 
The mean caffeine metabolic ratio increased 
significantly (2-fold), from 0.3 with the con-
sumption of kava to 0.6 at 30 days after ces-
sation of kava. This suggests that traditional 
kava drinking inhibits human CYP1A2 en-
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zyme activity. In view of this inhibitory ef-
fect, caution should be used in consumers of 
kava who are prescribed drugs that are me-
tabolized by CYP1A2 (e.g., theophylline, R-
warfarin, fluvoxamine, and tizanidine). On 
the other hand, CYP1A2 is responsible for 
the metabolic activation of potent carcino-
genic environmental toxins such as aflatox-
ins, and aflatoxin exposure is a problem in 
the warm and humid climate of the South 
Pacific. A previous study suggested an in-
verse correlation between cancer incidence 
and kava consumption for a number of Pacif-
ic Island Nations (Steiner, 2000). Therefore, 
inhibition of CYP1A2 by kava consumption 
may be of health benefit because kava con-
sumption could thus provide a protective ef-
fect against environmental carcinogens 
(Russmann et al., 2005). 
Overall, even though there were few clin-
ical studies conducted to assess the clinical 
relevance of potential CYP-mediated interac-
tions caused by kava, existing data indicate 
that kava supplements have the potential to 
inhibit a few CYP enzymes. The significant 
inhibitions caused by kava include CYP1A2 
and CYP2E1. Thus, taking kava dietary sup-
plements or drinking traditional aqueous ka-
va extract may result in an interaction with 
prescription drugs that are metabolized by 
either CYP1A2 or CYP2E1 enzyme. Caution 
is advised to be taken when the patients ad-
ministrate kava with CYP1A2 or CYP2E1 
substrate drugs because it may increase their 
therapeutic and adverse effects. 
 
Saw palmetto (Serenoa repens) 
Saw palmetto (Serenoa repens, Family- 
Arecaceae) is used in many forms of tradi-
tional herbal medicine. Native American In-
dians used the fruit for food and to treat a 
variety of urinary and reproductive system 
problems. Saw palmetto extract is an extract 
of the fruit of Serenoa repens and widely 
used as dietary supplement. It is abundant in 
fatty acids and phytosterols. It has been used 
in traditional and alternative medicine to 
treat a variety of disorders. It was reported 
that preparations of saw palmetto are well 
tolerated by most users and are not related 
with dangerous adverse incidents Saw pal-
metto extract is the most popular herbal 
preparations for the treatment of benign 
prostatic hyperplasia (Tacklind et al., 2002), 
a common condition in older men. Some 
people also use saw palmetto for colds and 
coughs, sore throat, asthma, chronic bronchi-
tis, chronic pelvic pain syndrome, and mi-
graine headache. In addition, saw palmetto is 
used as a diuretic, to promote relaxation (as a 
sedative), and to enhance sexual desire (as an 
aphrodisiac). 
Saw palmetto is used concomitantly with 
prescription medications. A recent study of 
men taking an herbal product for the treat-
ment of benign prostatic hyperplasia showed 
that 60 % of them were also taking a pre-
scription medication for benign prostatic hy-
perplasia (Eisenberg et al., 1998). Up todate, 
there is no evidence for drug interactions 
with saw palmetto. Two clinical studies have 
shown that saw palmetto had no significant 
effect on a number of CYP enzymes in 
healthy volunteers. The first study was con-
ducted in healthy volunteers to verify if a 
preparation of saw palmetto altered the activ-
ity of two important drug metabolizing en-
zymes, CYP2D6 and CYP3A4 (Markowitz 
et al., 2003). These two enzymes were se-
lected for assessment as, they together con-
tribute to the metabolism of more than 50 % 
of clinically used prescription and over-the-
counter medications (Wrighton and Thum-
mel, 2000; Zanger and Eichelbaum, 2000). 
The probe substrates dextromethorphan 
(CYP2D6 activity) and alprazolam 
(CYP3A4 activity) were administered orally 
at baseline and again after administration of 
saw palmetto (320 mg capsule once daily) 
for 14 days. The mean ratio of dextrome-
thorphan to its metabolite observed at the 
baseline was not significantly different from 
that after 14 days of saw palmetto admin-
istration. This indicates a lack of effect of 
saw palmetto co-administration on CYP2D6 
activity (Markowitz et al., 2003). There were 
no significant differences between the elimi-
nation half-life and AUC of alprazolam at 
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baseline and that after saw palmetto treat-
ment. This suggests that saw palmetto co-
administration has no effect on CYP3A4 ac-
tivity. Their results imply that extracts of 
saw palmetto at generally recommended 
doses are unlikely to alter the disposition of 
co-administered medications primarily me-
tabolized by human CYP2D6 or CYP3A4 
for elimination (Markowitz et al., 2003). 
However, these conclusions must be consid-
ered in the circumstance of the study's lim-
ited assessments and viewed as only the pre-
liminary study into the drug interaction po-
tential of saw palmetto. In the second clinical 
study (Gurley et al., 2004), single-time point 
phenotypic metabolic ratios were used to ex-
amine whether long-term supplementation of 
saw palmetto (Serenoa repens) extract af-
fected CYP1A2, CYP2D6, CYP2E1, or 
CYP3A4 activity. The study was carried out 
in 12 healthy volunteers. They were pretreat-
ed with saw palmetto for 28 days. Probe 
drug cocktails of midazolam and caffeine, 
followed 24 hours later by chlorzoxazone 
and debrisoquine, were administered before 
(baseline) and at the end of supplementation. 
Pre-supplementation and post-supplement-
ation phenotypic trait measurements were 
determined for CYP3A4, CYP1A2, 
CYP2E1, and CYP2D6 by use of 1-hydroxy-
midazo-lam/midazolam serum ratios (1-hour 
sample), paraxanthine/caffeine serum ratios 
(6-hour sample), 6-hydroxychlorzoxazone/ 
chlorzoxazone serum ratios (2-hour sample), 
and debrisoquine urinary recovery ratios (8-
hour collection), respectively. Comparisons 
of pre-supplementation and post-supple-
mentation phenotypic ratios suggested that 
saw palmetto supplements had no significant 
effect on CYP1A2, CYP2D6, CYP2E1, or 
CYP3A4 activity. The authors concluded 
that botanical supplements containing saw 
palmetto extract appear to pose a minimal 
risk for CYP-mediated herbal drug interac-
tions in humans (Gurley et al., 2004). The 
presently existing evidence indicates that 
saw palmetto is not likely to cause serious 
health threats to patients taking saw palmetto 
concomitantly with prescription drugs. 
Chinese herbal medicines 
Chinese herbs are part of traditional Chi-
nese medicine and have been used for thou-
sands of years in China (Leung, 2006). Re-
cently, Chinese herbs have become more 
popular in the Western world (Youns et al., 
2010). Many cancer patients often use Tradi-
tional Chinese Medicine (TMC) treatments 
to improve general health, to strengthen im-
munity and to reduce side effects of conven-
tional cancer therapies as well as to increase 
quality of life (Wong et al., 2001; Xu et al., 
2006; Youns et al., 2010). The traditional 
Chinese medicines are also used for treat-
ment of other diseases such as rheumatoid 
arthritis, obesity and HIV/AIDS (Zhang et 
al., 2010; Wang and Zou, 2011; Sui et al., 
2012). When patients take conventional 
drugs concomitantly with Chinese herbs, 
herbal drug interactions can occur and could 
produce unwanted outcomes. Some pharma-
codynamic interactions involved with Chi-
nese herbal medicines have been previously 
reported. For instance, concomitant admin-
istration of warfarin and some particular 
Chinese herbs including ginseng (ren shen), 
Ginkgo biloba (yin xing), Salvia miltiorrhiza 
(danshen), and Angelica sinensis (dong quai) 
has been found to initiate an increased INR 
(international normalized ratio). Usually ex-
tensive bleeding was observed in these pa-
tients as a consequence of the anticoagula-
tion and antiplatelet properties of these herbs 
(Fugh Berman, 2000; Izzo, 2005). With limi-
tation of our article’s scope, only reported 
pharmacokinetic interactions caused by these 
Chinese herbal medicines will be reviewed 
in detail. 
Moreover, Chinese herbs may also lead 
to pharmacokinetic interactions by modula-
tion of drug metabolizing enzyme activities 
(Lau et al., 2013; Yu et al., 2011), such as 
the phase I metabolizing CYP enzyme fami-
ly. Of this family, CYP3A4 is judged the 
most important enzyme because it is respon-
sible for the metabolism of most currently 
used drugs (Pal and Mitra, 2006; Scripture 
and Figg, 2006). Inhibition of CYP3A4 can 
lead to increased plasma levels of drugs that 
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are substrates for CYP3A4 and thus can 
cause toxicity. In contrast, induction of 
CYP3A4 can result in decreased plasma drug 
levels and subsequently diminish drug’s 
efficacy (Lau et al., 2013). Since numerous 
anticancer, immunosuppressive and antiviral 
drugs have a narrow therapeutic window, 
pharmacokinetic interactions between Chi-
nese herbs and conventional medications 
could have remarkable consequences. Even 
though Chinese herbs have the potential to 
cause pharmacokinetic and pharmacodynam-
ic interactions, patients usually believe they 
are safe to use because they are derived from 
natural sources (Lau et al., 2013; Youns et 
al., 2010). Little is also known regarding the 
risks and effects of interactions between tra-
ditional Chinese medicines and conventional 
medications. These Chinese herbal drug in-
teractions are also often under-testified (Fas-
inu et al., 2012; Fugh Berman, 2000; Ge et 
al., 2014). In this review, possible drug in-
teractions with ginseng (ren shen) has been 
described in this current report, while those 
with Ginkgo biloba (yin xing) were dis-
cussed before in previous review article – 
Part 1 published in this journal (Wanwimol-
ruk and Prachayasittikul, 2014). Some other 
important Chinese medicines and possible 
drug interactions are reviewed as follow.  
 
(i) Danshen (Salvia miltiorrhiza)  
Danshen, also recognized as Chinese sal-
via or red salvia, are herbal preparations de-
rived from the roots and rhizome of Salvia 
miltiorrhiza (Family Lamiaceae). Danshen is 
commonly used in traditional Chinese medi-
cine for the treatment of numerous condi-
tions including cardiovascular disease, hy-
pertension, and ischemic stroke (Ernst et al., 
2008; Hatfield et al., 2013; Izzo, 2012). 
Danshen can affect haemostasis in several 
ways, including inhibition of platelet aggre-
gation. Case reports have identified danshen 
as an agent that caused the overanticoagula-
tion and bleeding complications in patients 
who were become stable on warfarin therapy 
and took this herbal preparation concomi-
tantly (Chan 2001; Yu et al., 1997). Studies 
in rats have shown that danshen can increase 
the bioavailability of both R- and S-warfarin 
(Chan et al., 1995), therefore magnifying the 
anticoagulant response of warfarin. Not sur-
prisingly, patients receiving warfarin therapy 
may present with overanticoagulation and 
bleeding complications when they also take 
danshen (Chan 2001). Because of the risk of 
these pharmacokinetic and pharmacodynam-
ic interactions, danshen should be avoided in 
patients taking warfarin. 
In recent years, some studies have re-
vealed the effect of danshen extract on 
CYP3A4. Ethyl acetate extract (lipophilic 
components) of danshen has shown to be 
able to induce CYP3A in C57BL/6J mice 
(Kuo et al., 2006). Yu et al. (2009) have 
demonstrated that lipophilic components of 
danshen extract (tanshinone IIA and crypto-
tanshinone) were good agonists for pregnane 
X receptor (PXR) involved in the induction 
of CYP3A4. Treatment of LS174T cells with 
cryptotanshinone or tanshinone IIA caused a 
significant increase of CYP3A4 mRNA (Yu 
et al., 2009). They concluded that activation 
of PXR and the resultant CYP3A4 induction 
was facilitated by cryptotanshinone and 
tanshinone IIA, the active components of 
danshen. An in vitro study using liver micro-
somes reported that seven (three lipophilic 
and four hydrophilic) components of dans-
hen extract had no inhibitory effect on 
CYP3A4 enzyme activity (Qiu et al., 2008). 
These findings suggested that danshen ex-
tract could induce human CYP3A4 enzymes 
and this can lead to significant drug interac-
tion with CYP3A4 substrate drugs. This was 
supported by finding from a clinical study 
conducted in 14 healthy volunteers (Qiu et 
al., 2010). Long term (14 days) administra-
tion of danshen tablets caused a significant 
decrease in oral bioavailability of midazo-
lam, a preferred in vivo CYP3A probe. This 
may be the cause of the induction of intesti-
nal CYP3A4 by the lipophilic components of 
danshen extract (Qiu et al., 2010). Of note, if 
an orally administered drug is a CYP3A4 
substrate with a low oral bioavailability be-
cause of extensive pre-systemic metabolism 
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by enteric CYP3A4, then co-administration 
of danshen tablets may have a substantial 
effect on systemic exposure. Thus, precau-
tions should be taken when patients are tak-
ing danshen tablet concomitantly with 
CYP3A4 substrate drugs (Qiu et al., 2010). 
This will depend upon the drug’s exposure-
response relationship. It may require dosage 
adjustment of CYP3A4 substrate drugs in 
patients receiving concomitant therapy with 
danshen preparations (Qiu et al., 2010). In 
addition, an extensive review on the effects 
of danshen and its active ingredients on the 
interactions of CYP and drug transporters 
have been published recently (Zhou et al., 
2012).  
 
(ii) Dong Quai (Angelica sinensis)  
Angelica sinensis (Family Apiaceae), 
commonly recognized as “dong quai”,“dong 
gui” or dang gui (various spellings), is one of 
the most popular traditional Chinese medi-
cines (Capasso et al., 2003; Hirata et al., 
1997; Kan et al., 2008). Preparations from its 
roots are used mainly for dysmenorrhea and 
menopausal symptoms (Circosta et al., 2006; 
Hirata et al., 1997). It is also used for the 
treatment of anemia, chronic bronchitis, 
asthma, rheumatism and cardiovascular dis-
eases (Tang et al., 2006). It is recorded that 
70 formulae in China and 56 formulae in Ja-
pan contain dong quai. Dong quai is com-
monly used in Asia, and dong quai is also 
consumed as a health food product for wom-
en’s care in Europe and America. The ac-
tions of dong quai are thought to be due to 
the presence of a number of chemical con-
stituents, including coumarins, which may 
have anticoagulant actions (Capasso et al., 
2003; Lau et al., 2013). Two case reports 
were recorded and suggested that the major 
consequences of warfarin and dong quai in-
teraction were increased bleeding risks due 
to the additive anticoagulant or antiplatelet 
effects of dong quai (Ellis and Stephens, 
1999; Page and Lawrence, 1999; Tsai et al., 
2013). For patients taking conventional anti-
coagulants such as warfarin concomitantly 
with dong quai, the potential risks of in-
creased bleeding as a consequence of herbal 
drug interactions must not be overlooked 
(Tsai et al., 2013). The effects of dong quai 
directly on CYP activities were solely inves-
tigated in in vitro (Lau et al., 2013; Tang et 
al., 2006). Even though these in vitro results 
showed strong inhibition or induction of 
dong quai against a number of human CYP 
enzymes including CYP1A2, CYP2D6, 
CYP2C9, CYP2E1 and CYP3A4, the conse-
quence of these interactions is necessary to 
be proved by clinical studies. If the data are 
extrapolated to humans, these changes might 
be very critical, especially when this Chinese 
medicine is used over long periods of time. 
Under these conditions, the enzymatic induc-
tion/inhibition would be long-lasting, and 
alterations in the pharmacokinetics of con-
comitant drugs can happen (Guerra et al., 
2000). Thus, attention should be given to the 
possible drug interaction in patients concur-
rently using dong quai and drugs that are 
CYP substrates. Lack of clinical studies on 
drug interactions with this popular Chinese 
medicine dong quai, suggests future research 
on this area is crucially warranted. 
 
(iii) Bai Hua She She Cao  
(Oldenlandia diffusa) 
Oldenlandia diffusa (Willd.) Roxb. is a 
member of the Rubiaceae Family. The plant 
is known as Hedyotis diffusa (botanical 
name), Herba hedyotis diffusae (pharma-
ceutical name) and Bai Hua She She Cao as 
a common Chinese name. It is a well-known 
medicinal plant commonly used in Southern 
China for the treatment of hepatitis, tonsilli-
tis, sore throat, appendicitis, urethral infec-
tion, rheumatism, arthritis, autoimmune dis-
ease, and malignant tumors of the liver, lung, 
and stomach (Gupta et al., 2004; Ovesna et 
al., 2004).  
Oldenlandia diffusa was found to slightly 
inhibited CYP3A4 activity in vitro (Lau et 
al., 2013). However, its potency on inhibi-
tion of CYP3A4 was much less than keto-
clonazole. Interestingly, Oldenlandia diffusa 
was reported to cause significant induction of 
both PXR-mediated CYP3A4 and CYP3A4 
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mRNA levels (Lau et al., 2013). These re-
sults have shown that the strength of the 
CYP3A4 induction mediated by Oldenlandia 
diffusa was as strong as caused by rifampicin 
and St. John's wort, two very potent 
CYP3A4-inducers and well-known in clini-
cal setting (Lau et al., 2013). Coadministra-
tion of rifampicin or St. John's wort with a 
CYP3A4 substrate drug was known to de-
crease plasma levels of CYP3A4 drugs, such 
as the anticancer drug imatinib, the immuno-
suppressant cyclosporine and the antiviral 
drug indinavir (Borrelli and Izzo, 2009; 
Niemi et al., 2003). Thus, herbal drug inter-
actions caused by taking Oldenlandia diffusa 
concomitantly with these CYP3A4 drugs are 
highly possible. As this Chinese herb Olden-
landia diffusa is commonly used for treat-
ment of various illnesses including cancers 
(Gupta et al., 2004; Ovesna et al., 2004), po-
tential Chinese herbal drug interactions need 
to be evaluated in vivo. This may be very 
feasible in cancer patients already consuming 
Chinese herbs in conjunction with their 
chemotherapy. These patients could be suit-
able candidates to evaluate pharmacokinetic 
interactions between Chinese herbs and anti-
cancer drugs.  
 
(iv) Dang shen (Codonopsis tangshen) 
Dang shen or Chuan-Denshen is the root 
of Codonopsis tangshen, Oliv. (Family 
Campanulaceae). It is a well-known tradi-
tional Chinese medicine, sometimes used as 
a cheap substitute for ginseng. This Chinese 
medicine has been used as a traditional rem-
edy for replenishing energy deficiency, 
strengthening the immunological system, 
lowering blood pressure and improving ap-
petite (Fu et al., 1999; Juangsu New Medical 
College, 1979). Codonopsis tangshen roots 
have also been demonstrated to possess other 
pharmacological effects such as antiulcer 
activities, antiplatelet activities and anti-
cancer activities (Fu et al., 1999). Despite the 
wide use of this Chinese herbal medicine, 
there is very little information on drug inter-
actions with Codonopsis tangshen. To our 
knowledge, there was only one in vitro study 
that investigated the possible interactions of 
selected Chinese herbs including Codonopsis 
tangshen on human CYP3A4 enzyme (Lau et 
al., 2013). As compared with other Chinese 
medicines (Oldenlandia diffusa and 
Rehmannia glutinosa), Lau and co-workers 
(Lau et al., 2013) found that Codonopsis 
tangshen hardly induced CYP3A4. In addi-
tion, Codonopsis tangshen slightly inhibited 
CYP3A4 enzyme activity. However, its in-
hibitory effect was observed to be much less 
than that of other two Chinese medicines, 
i.e., Oldenlandia diffusa and Rehmannia glu-
tinosa (Lau et al., 2013). These results may 
imply that drug interactions with Codonopsis 
tangshen are unlikely, at least with regarding 
to the important human drug metabolizing 
enzyme CYP3A4. Nevertheless, clinical 
studies are required to confirm the lack of 
drug interactions with this particular herbal 
medicine. 
 
(v) Sheng di huang (Rehmannia glutinosa) 
Rehmannia glutinosa is one of the fifty 
principal herbs used in traditional Chinese 
medicine, where it has the name “Sheng Di 
Huang” in Chinese, and known as Sook-Ji-
Whang or To-Byun in Korea. A steamed root 
of Rehmannia glutinosa has been used for 
regulation of immune response and shown to 
improve memory (Cui et al., 2003). It has 
also been reported that Rehmannia glutinosa 
possesses anti-allergy effects and anti-
inflammatory functions (Kim et al., 1998, 
1999; Sung et al., 2011; Wu et al., 2011). 
Only a few in vitro studies have been con-
ducted to determine the effects of Rehman-
nia glutinosa on activity of human CYP en-
zymes. Yu and co-workers (Yu et al., 2011) 
have shown that ethanol extracts of 22 tradi-
tional Chinese medicines including Rehman-
nia glutinosa could activate PXR signalling 
pathway and induce CYP3A4 reporter gene. 
Thus, it has been suggested that caution 
should be taken when Rehmannia glutinosa 
and other Chinese herbal medicines are used 
in combination with prescribed drugs metab-
olized by CYP3A4 (Yu et al., 2011). On the 
other hand, the finding from another in vitro 
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study gave contradictory results. This study 
was carried to evaluate the potential for 
herbal drug interactions of CP-001, a stand-
ardized herbal mixture of Houttuynia cor-
data, Rehmannia glutinosa, Betula platyphyl-
la, and Rubus coreanus (Yoo et al., 2013). 
Rehmannia glutinosa is one of the compo-
nents in this CP-001 herbal mixture. The 
study was tested by using in vitro human liv-
er microsomal technique. The effects of CP-
001 on activities of various CYP isozymes 
(i.e., CYP1A2, CYP2A6, CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4) were 
found to be negligible. Thus, the likelihood 
of drug interactions caused by this herbal 
mixture is considered minimal. The findings 
may be extrapolated and applied to Rehman-
nia glutinosa when it is given as a single 
herbal medicine. Normally, this would ex-
pect that the concomitant use of Rehmannia 
glutinosa with prescription drugs, is unlikely 
to cause any significant drug interactions. As 
no clinical studies have been conducted to 
confirm this, the findings from in vitro inves-
tigations may not always be valid. To clarify 
the clinical relevance of the proposed drug 
interactions with the popular Chinese herbal 
medicine Rehmannia glutinosa, further stud-
ies are required. 
 
Quality of herbal medicines as a  
problematic issue  
Of note, as most described drug interac-
tions with Chinese herbs were derived from 
in vitro investigations, these must be extrap-
olated to clinical settings with precaution. 
For example, the interactions between Chi-
nese medicines and CYP3A4 will only have 
clinical relevance, if the minimal concentra-
tion of herbal ingredients needed to cause 
these interactions is achieved in vivo (Lau et 
al., 2013). This is dependent upon the physi-
cochemical and pharmacokinetic properties 
of those herbal active ingredients, such as 
their lipid solubility, oral bioavailability, ab-
sorption, distribution and elimination. More-
over, some other factors such as variation 
between batches of Chinese medicine prod-
ucts and methods of herbal preparations can 
further complicate the impact of Chinese 
herbal drug interactions. Quality control is a 
major problem associated with herbal medi-
cines because the manufacture of herbal 
medicines is not subject to the same regula-
tions as prescription drugs (Wanwimolruk 
and Prachayasittikul, 2014). Thus, the con-
tent of the active ingredients may vary 
among manufacturers or product batches, 
possibly causing a large variation in efficacy 
and safety. Different batches of Chinese 
herbs can have different compositions of in-
gredients, including the active compounds 
which are able to modulate activity of 
CYP3A4 enzyme (Lau et al., 2013). There-
fore, various batches can have different con-
sequences on herbal drug interactions. As 
reported for Rehmannia glutinosa (Zhang et 
al., 2008), the processing of raw herbs can 
lead to differences in herbal compositions 
among the batches. These differences in 
herbal active composition will impact the 
overall outcome of herbal drug interactions. 
It may produce contrasting results in herbal 
drug interactions when compared to the re-
sults derived from different studies. Products 
from different manufacturers of the same 
herb may have different active herbal com-
positions and hence different biological ef-
fects are produced. Also these may cause 
different outcomes of herbal drug interac-
tions such as one may produce significant 
drug interactions whereas the other causes no 
significant interactions. The problem of lack 
of quality control of herbal products causing 
variation in their active ingredients is a main 
concern for every herbal product, not only 
for Chinese medicines. This has been recog-
nized with three well-known herbal supple-
ments including St. John’s wort, ginseng and 
ephedra. The contents of active ingredients 
in these herbal supplements were reported to 
vary widely between brands and in some 
cases the content variation was also found 
between batches of the same herbal products 
(Draves and Walker 2003; Gurley et al., 
2000; Harkey et al., 2001). Therefore, it has 
been proposed that the same rigorous regula-
tions that apply to conventional drugs with 
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respect to quality, safety and efficacy should 
be demanded for herbal medicines. 
 
CONCLUSION 
Herbal medicines have been commonly 
used over thousands of years, and they have 
gained popularity over the last decades. Now 
it is well recognized that herbal drug interac-
tions are real and have potential to occur 
when patients take herbal medicines con-
comitantly with conventional drugs. The 
most important example of herbal drug inter-
actions is the interactions with St. John’s 
wort as these interactions have caused signif-
icant clinical outcomes. Details of the St. 
John’s wort drug interactions are described 
in previous review articles (Hu et al., 2005; 
Izzo and Ernst, 2009; Johne and Roots, 
2005; Shi and Klotz, 2012; Wanwimolruk 
and Prachayasittikul, 2014). Many studies 
have been focused on trying to identify po-
tential herbal drug interactions. Unfortunate-
ly, most of these investigations were carried 
out either in animals or in vitro. It is com-
mon that there were discrepancies between 
results of animal or in vitro studies and those 
derived from human studies. Therefore, cau-
tion must be exercised both in the absence of 
human studies and with respect to reliance 
on lab-based evidence (Shi and Klotz, 2012). 
With existing evidence in humans, the herbs 
described in this review, only kava and green 
tea have shown significant potential for 
herbal drug interactions, especially when 
they are taken with narrow therapeutic drugs. 
In contrast, other well-studied herbs includ-
ing black cohosh, ginseng, grape seed extract 
and saw palmetto appeared to present no 
drug interactions or cause a minor interac-
tions with drugs that are metabolized by hu-
man CYP enzymes. With respect to Chinese 
herbal medicines, although they are widely 
used among Asian people, their potential in-
teractions with conventional medicines may 
be under reported. Importantly, there is lack 
of evidence in humans to verify if the poten-
tial drug interactions with Chinese herbal 
medicines exist and have clinical conse-
quence. Many existing data on drug interac-
tions with Chinese medicines are derived 
from either in vitro or animal studies. There-
fore, this urges us to pay attention to conduct 
clinical studies which will help to prove clin-
ical relevance of the drug interactions with 
Chinese medicines.    
In summary, herbal drug interactions be-
tween herbs and conventional medicines can 
occur. These are often mediated through 
modifications of the important human CYP 
enzymes as most clinically used drugs are 
substrates of CYP. Evidence has been 
demonstrated clearly that herbal drug inter-
actions can be of clinical relevance. There-
fore, caution should be taken when patients 
take herbal medicines or herbal supplements 
together with conventional medicines. Con-
sultation with patients regarding the use of 
herbal medicines is essential. Currently, the 
awareness of herbal drug interactions is im-
proving as we have more information dis-
seminated and academic courses including 
this topic are taught in schools of medicines 
and allied health. Despite this, efforts dedi-
cated to prevent herbal drug interactions 
needs to continue. Further research to inves-
tigate the clinical relevance of the interac-
tions caused by herbs and herbal medicines 
in particular Chinese traditional medicines 
and other Asian (e.g. Indian, Thai) herbal 
medicines, is required. 
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